T2 Biosystems (NASDAQ:TTOO – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, February 15th. Individual interested in participating in the company’s earnings conference call can do so using this link.
T2 Biosystems (NASDAQ:TTOO – Get Free Report) last posted its quarterly earnings data on Tuesday, November 14th. The medical equipment provider reported ($3.45) EPS for the quarter. The business had revenue of $1.47 million during the quarter.
T2 Biosystems Stock Up 32.7 %
Shares of TTOO opened at $6.49 on Tuesday. T2 Biosystems has a 12-month low of $3.36 and a 12-month high of $142.00. The stock’s fifty day simple moving average is $4.69 and its 200-day simple moving average is $20.67.
Wall Street Analysts Forecast Growth
Institutional Investors Weigh In On T2 Biosystems
Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in T2 Biosystems in the 3rd quarter valued at approximately $28,000. Tudor Investment Corp Et Al acquired a new position in shares of T2 Biosystems during the 3rd quarter worth approximately $42,000. Virtu Financial LLC increased its position in shares of T2 Biosystems by 1,763.1% during the 2nd quarter. Virtu Financial LLC now owns 323,427 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 306,067 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of T2 Biosystems by 449.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 538,540 shares of the medical equipment provider’s stock worth $61,000 after purchasing an additional 440,531 shares during the last quarter. Finally, Anson Funds Management LP acquired a new position in shares of T2 Biosystems during the 1st quarter worth approximately $242,000. Institutional investors and hedge funds own 3.74% of the company’s stock.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
- Five stocks we like better than T2 Biosystems
- Stock Sentiment Analysis: How it Works
- 3 attractive stocks that insiders are buying
- What is the Australian Securities Exchange (ASX)
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.